UP Standard Of Care in AS with Upadacitiniby Sponsored by Abbvie
Objectives
This symposium will take you through understanding of axSpA spectrum & patient burden, comprehensive review on diagnosis & treatment guidelines, and factors to be considered in your routine clinic sessions. Upadacitinib can provide clinical benefit for patients encompassing nr-axSpA & r-axSpA, differential pain control as well as EMM management, and also long- term treatment goal of slowing down radiographic progression. Please attend the symposium and explore how to improve standard of care in AS with upadacitinib.
| Agenda - Friday 30 October | |
|---|---|
|
|
Chairperson: Dr Taehwan Kim, Republic of Korea
|
|
1025-1030 |
Opening remarks
Dr Taehwan Kim, Republic of Korea |
|
1030-1110 |
1. Understanding of axSpA spectrum and patient burden 2. Can axSpA spectrum from nr-axSpA to r-axSpA be optimally managed with Upadacitinib? 3. Diagnosis and treatment guidelines 4. Things to consider for routine clinical practice 5. My clinical experience Prof Xenofon Baraliakos, Germany |
|
1110-1120 |
|
|
1120-1125 |
Closing remarks
Dr Taehwan Kim, Republic of Korea |
